gvtcx

NHS National Framework for Transition products (Nilotinib and Ticagrelor)

NHS England Published 20 Aug 2025 Find a Tender
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£29,042,000 (£34,850,400 inc. VAT)
Statuscomplete
Category (CPV) 33600000
RegionNorth East, North West, East Midlands, West Midlands, East of England, South East, South West
Deadline9 Jun 2025
Procedureopen
SME suitableYes
OCIDocds-h6vhtk-04ff90

Awards (15)

This procurement was awarded to 15 suppliers. Values shown are per-award; the notice total is £29,042,000.

SupplierValueDateStatus
Accord-UK Ltd shared £22,097,000 11 Jun 2025 active
ACCORD-UK LTD shared £22,097,000 11 Jun 2025 pending
AstraZeneca shared £22,097,000 11 Jun 2025 active
ASTRAZENECA UK LIMITED shared £22,097,000 11 Jun 2025 pending
C. S. T. PHARMA LIMITED shared £22,097,000 11 Jun 2025 pending
Dr.Reddy's Laboratories (UK) Limited shared £22,097,000 11 Jun 2025 active
DR REDDY'S LABORATORIES (UK) LIMITED shared £22,097,000 11 Jun 2025 pending
MSN Laboratories Europe Limited shared £22,097,000 11 Jun 2025 active
MSN LABORATORIES EUROPE LIMITED shared £22,097,000 11 Jun 2025 pending
NOVARTIS PHARMACEUTICALS UK LIMITED shared £22,097,000 11 Jun 2025 pending
Novartis Pharmaceuticals UK Ltd shared £22,097,000 11 Jun 2025 active
ZENTIVA PHARMA UK LIMITED shared £22,097,000 11 Jun 2025 pending
Zentiva Pharma UK Ltd shared £22,097,000 11 Jun 2025 active
Zydus Pharmaceuticals UK Ltd shared £22,097,000 11 Jun 2025 active
ZYDUS PHARMACEUTICALS UK LTD shared £22,097,000 11 Jun 2025 pending

description

Project title: NHS National Framework for Transition products (Nilotinib and Ticagrelor) commencing 1st September 2025

Offer reference number: CM/TNS/24/5721

Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.

Potential periods of call-offs under the framework agreement:

CM/TNS/24/5721/01 - Nilotinib and Ticagrelor

Lot 1 DCE/DNW/DNE: 01/09/2025 to 31/01/2027 (17 months)

Lot 2 DLN/DLS/DSW: 01/09/2025 to 31/01/2027 (17 months)

Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

Please note that the contract had erroneously been advertised as an open framework at the tender stage and should have been advertised as a standalone framework.

Additional Unsuccessful supplier not listed due to technical error:

Torrent Pharma (UK) Ltd

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

7 notices published against this procurement.

PublishedTypeRegimeNotice
9 Apr 2025 Preliminary market engagement (UK2) Procurement Act 2023 013938-2025
9 Apr 2025 Preliminary market engagement (UK2) Procurement Act 2023 013939-2025
7 May 2025 Tender notice (UK4) Procurement Act 2023 019302-2025
7 May 2025 Tender notice (UK4) Procurement Act 2023 019321-2025
11 Jul 2025 Contract award (UK6) Procurement Act 2023 039171-2025
11 Jul 2025 Contract award (UK6) Procurement Act 2023 039270-2025
20 Aug 2025 Contract details (UK7) Procurement Act 2023 049985-2025

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.